Lenalidomide Sandoz 5 Mg Hard Capsules (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, leading to targeted degradation of transcription factors Ikaros and Aiolos. This results in altered cytokine production, inhibition of angiogenesis, and induction of apoptosis in malignant plasma cells.

The dose of Lenalidomide Sandoz 5 mg capsules is individualized by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Lenalidomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It should not be used by pregnant women, and effective contraception is required during treatment and for a defined period after discontinuation. Breastfeeding is also contraindicated.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide is more potent and has a different safety profile than thalidomide, offering higher response rates and lower neuropathy risk. Compared with pomalidomide, it is generally used earlier in therapy and has a broader indication set, while pomalidomide is reserved for later‑line treatment in certain refractory cases.

Store Lenalidomide Sandoz 5 mg hard capsules at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lenalidomide is taken orally, usually with a glass of water. The capsule can be swallowed whole with or without food, unless the prescriber advises otherwise. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), severe neutropenia leading to infection, severe thrombocytopenia causing bleeding, and the potential development of secondary primary malignancies. Prompt medical attention is required if any of these events are suspected.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe renal or hepatic impairment unless specifically directed by a specialist. It is also contraindicated in patients who cannot comply with the required risk‑evaluation and mitigation strategies.